Twist Bioscience (TWST) CFO Laponis Adam Sells $385K of Stock

Adam Laponis, the Chief Financial Officer of Twist Bioscience Corporation (NasdaqGS: TWST), sold 2,462 shares on October 9, 2026. The sale was valued at approximately $384,823, with shares priced at $156.30 each. This transaction was not planned in advance.

Inside Laponis's Trade

Laponis's recent sale adds to a pattern of insider trading at Twist Bioscience. Earlier in October, other executives, including Dennis Cho and Patrick John Finn, sold shares as well. Cho sold over 9,500 shares on October 2, while Finn sold more than 25,700 shares on the same day. These trades indicate ongoing activity among the company's leadership.

Other Institutional Activity in Twist Bioscience

Several other institutional investors have been active with Twist Bioscience shares. Blackrock Inc. increased its stake by 279,391 shares, bringing its total to 5,833,891 shares worth about $774.4 million. Meanwhile, FMR, LLC added 2,813,133 shares, raising its holdings to 4,703,044 shares valued at approximately $624.3 million. Conversely, Artisan Partners Limited Partnership reduced its holdings by 1,565,861 shares, ending with 4,802,017 shares worth about $637.5 million.

Twist Bioscience Corporation Stock Down 8.0%

The stock recently traded around $132.86, which is below its 50-day moving average of $147.44 by about 9.9%. It is also significantly below its 52-week high of $219.71, by approximately 39.5%. However, it remains well above its 52-week low of $23.30, reflecting a strong recovery over the past year.

Recent Earnings

Twist Bioscience reported trailing twelve-month revenue of approximately $431.8 million, with a year-over-year revenue growth of 23.2%. However, the company has faced challenges, with a net margin of -31.7% and a return on equity of -29.6%. The next earnings report is scheduled for November 16, 2026.

Insider Buying and Selling at Twist Bioscience Corporation

In addition to Laponis's recent sale, other insiders have also sold shares. Dennis Cho sold 9,514 shares on October 2 at a price of $188.88, totaling about $1.8 million. President Patrick John Finn sold 25,714 shares on the same day, also at $188.88, amounting to roughly $4.9 million. CEO Emily Leproust sold 4,548 shares on October 5, with a total value of about $919,374.

Analysts Set New Price Targets

Analysts have maintained varied ratings for Twist Bioscience recently. On October 7, Barclays maintained an Overweight rating with a target price of $215, while Guggenheim maintained a Buy rating with a target of $212 on October 1. However, BWS Financial continues to rate the stock as a Sell with a target of $45. The consensus among 12 analysts gives a mean price target of $163.67, reflecting a potential upside from current levels.

About Twist Bioscience

Twist Bioscience Corporation develops and sells synthetic DNA-based products, primarily serving the biotechnology sector. The company is known for its innovative approach to DNA synthesis, which supports various applications in healthcare and research. As it navigates recent insider trading and analyst opinions, its financial performance and upcoming earnings report will be closely watched.

Bottom Line

Investors should keep an eye on Twist Bioscience as it prepares for its next earnings report on November 16, 2026. The recent insider selling and mixed analyst ratings reflect ongoing market interest and the company's position in the biotechnology sector.